Norges Bank
NRIX icon

Norges Bank’s Nurix Therapeutics NRIX Stock Holding History

Norges Bank’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-318,800
Closed -$6.01M – 1815
2024
Q4 		$6.01M Hold
318,800
– – ﹤0.01% 1458
2024
Q3 		$7.16M Sell
318,800
-188,736
-37% -$4.28M ﹤0.01% 1434
2024
Q2 		$10.6M Buy
507,536
+326,736
+181% +$5.09M ﹤0.01% 1381
2024
Q1 		$2.66M Sell
180,800
-77,600
-30% -$835K ﹤0.01% 1708
2023
Q4 		$2.67M Buy
+258,400
New +$1.77M ﹤0.01% 1771

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank's NRIX Position: Q1 2025 in Review

Norges Bank sold out of Nurix Therapeutics (NRIX) in Q1 2025, closing a stake of 318,800 shares — an estimated $6.01M sold.

Norges Bank first reported a position in NRIX in Q4 2023 and held it in 5 quarters. The position peaked at $10.6M in Q2 2024. 170 funds tracked by Wall St. Rank hold NRIX as of Q1 2025.

  • Norges Bank reported no remaining Nurix Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Norges Bank sold 318,800 Nurix Therapeutics shares in Q1 2025, an estimated $6.01M.
  • Norges Bank first reported a position in Nurix Therapeutics in Q4 2023 and held it in 5 quarters.
  • Norges Bank's Nurix Therapeutics position peaked at $10.6M in Q2 2024.
  • 170 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2025.

Based on Norges Bank's 13F filing for Q1 2025, filed 13 May 2025.